Previous Article | Next Article 
Mol Cell Biol, March 1998, p. 1534-1543, Vol. 18, No. 3
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Mutations in the Yeast KEX2 Gene Cause a
Vma
-Like Phenotype: a Possible Role for the Kex2
Endoprotease in Vacuolar Acidification
Yemisi E.
Oluwatosin and
Patricia M.
Kane*
Department of Biochemistry and Molecular
Biology, SUNY Health Science Center at Syracuse, Syracuse, New York
13210
Received 14 August 1997/Returned for modification 24 September
1997/Accepted 10 December 1997
 |
ABSTRACT |
Mutants of Saccharomyces cerevisiae that lack vacuolar
proton-translocating ATPase (V-ATPase) activity show a well-defined set
of Vma
(stands for vacuolar membrane ATPase activity)
phenotypes that include pH-conditional growth, increased calcium
sensitivity, and the inability to grow on nonfermentable carbon
sources. By screening based on these phenotypes and the inability of
vma mutants to accumulate the lysosomotropic dye quinacrine
in their vacuoles, five new vma complementation groups
(vma41 to vma45) were identified. The
VMA45 gene was cloned by complementation of the
pH-conditional growth of the vma45-1 mutant strain and
shown to be allelic to the previously characterized KEX2
gene, which encodes a serine endoprotease localized to the late Golgi
compartment. Both vma45-1 mutants and kex2 null
mutants exhibit the full range of Vma
growth phenotypes
and show no vacuolar accumulation of quinacrine, indicating loss of
vacuolar acidification in vivo. However, immunoprecipitation of the
V-ATPase from both strains under nondenaturing conditions revealed no
defect in assembly of the enzyme, vacuolar vesicles isolated from a
kex2 null mutant showed levels of V-ATPase activity and
proton pumping comparable to those of wild-type cells, and the V-ATPase
complex purified from kex2 null mutants was structurally indistinguishable from that of wild-type cells. The results suggest that kex2 mutations exert an inhibitory effect on the
V-ATPase in the intact cell but that the ATPase is present in the
mutant strains in a fully assembled state, potentially capable of full enzymatic activity. This is the first time a mutation of this type has
been identified.
 |
INTRODUCTION |
A distinct class of
proton-translocating ATPases, the vacuolar-type ATPases (V-ATPases), is
responsible for acidifying the eukaryotic vacuolar network, including
the vacuole or lysosome, Golgi apparatus, endosomes, clathrin-coated
vesicles, and regulated secretory vesicles (9). The
Saccharomyces cerevisiae vacuole is an acidic organelle
functionally equivalent to the mammalian lysosome and the plant vacuole
(50). It is involved in metabolite storage, macromolecular
degradation, and calcium and amino acid homeostasis (2). The
yeast V-ATPase is a multisubunit enzyme consisting of at least 12 different polypeptides encoded by the VMA genes (2,
27, 63; reference 15 and references
therein). As in F1F0-ATPases, the enzyme is
made up of two domains in the yeast V-ATPase: the peripheral sector
(the V1 sector), which contains the catalytic
ATP-hydrolyzing domain and is peripherally associated with the
cytoplasmic face of the vacuolar membrane, and the integral membrane
sector (the V0 sector), which contains the proton pore (27).
Many of the genes that encode the yeast V-ATPase subunits, including
VPH1, STV1 (a functional homolog of
VPH1), VMA1 to -8, -10,
-11, and -13, have been cloned (4, 14, 22,
23, 38, 39, 44, 58, 63, 66, 69). In addition, four genes which are required for assembly of the V-ATPase but are not part of the final
active complex (VMA12, VMA21, VMA22,
and VPH6) have been cloned (17, 19-21). In
total, 17 genes have been identified as essential for V-ATPase
activity. Deletion of any of these genes leads to the loss of vacuolar
acidification and a conditional lethality in the resulting
vma (stands for vacuolar membrane H+-ATPase
activity) mutants; the mutants fail to grow on media buffered to pH 7 or higher (43, 69), medium containing high concentrations of
calcium (45), or medium containing a nonfermentable carbon source (45), but they retain the ability to grow on medium
buffered to pH 5.0 (43, 69). Vma
cells fail to
accumulate the fluorescent weak base, quinacrine, in their vacuoles,
indicating loss of vacuolar acidification (69).
V-ATPases are present in several distinct locations within a single
cell, and it is not yet clear how the enzyme is targeted to different
cellular locations or regulated such that different organelles are
acidified to different degrees (reviewed in reference 10). It is possible that one or more of the subunits
may be involved in targeting and/or regulation. Isoforms have been
identified for two of the V-ATPase subunits, the 17-kDa proteolipid and
the 100-kDa integral membrane subunit (38, 66), and there is
evidence that the two 100-kDa subunit isoforms are localized to
different cellular locations (38). It also appears that a
small collection of nonsubunit proteins may play an essential role in
assembling, regulating, and targeting V-ATPase (21, 27).
Three genetic screens have been used to identify gene products required
for V-ATPase activity. The VPH1, VPH2 (which is
the same as VMA12), and VPH6 genes were
identified in a screen for vacuolar pH mutants (vph
[39, 48]), the VMA11, VMA12, and VMA13 genes were identified in a screen for
calcium-sensitive strains showing a petite phenotype (cls
[21]), and the VMA5 and VMA21-23
genes were identified in a screen for failure to accumulate a colored
adenine precursor in the vacuole (22). The vph
screen did not isolate mutations in any of the previously identified
VMA genes, the cls screen identified alleles of
VMA1 and VMA3 in addition to five novel genes,
and the vma screen isolated mutations in the VMA1
gene in addition to four novel genes (21, 22, 39, 48). The
combined results from these screens indicate that the screening process
is not yet saturated.
Using the Vma
phenotypes described above, we designed a
genetic screen to identify novel mutant yeast strains lacking vacuolar acidification in order to better understand the subunit composition, assembly, and function of V-ATPase. In this study, we describe the
identification of five new complementation groups whose activities are
required for vacuolar acidification by yeast V-ATPase. In particular,
we show that the Kex2 endoprotease is required for activity of V-ATPase
in vivo.
 |
MATERIALS AND METHODS |
Materials.
Restriction endonucleases were purchased from New
England Biolabs or from Boehringer Mannheim, and Taq DNA
polymerase was purchased from Boehringer Mannheim. Zymolyase 100T and
Tran35S-label were purchased from ICN. 35S-dATP
was purchased from DuPont-NEN. A 1-kb DNA ladder and prestained and
14C-labeled protein molecular mass standards were obtained
from Life Technologies, Inc. Dithiobis(succinimidylpropionate) was purchased from Pierce. Glusulase was obtained from DuPont. Zwittergent 3-14 detergent was purchased from Calbiochem. All other reagents were
purchased from Sigma.
Strains, media, and microbiological techniques.
Yeast
strains used in this study and their genotypes are listed in Table
1. Yeast media were prepared as described
by Sherman et al. (57). Buffered medium was prepared as
described by Yamashiro et al. (69), except that 50 mM MES
(2-[N-morpholino]ethanesulfonic acid) and 50 mM MOPS
(2-[N-morpholino]propanesulfonic acid) were used to buffer
YEPD (yeast extract-peptone-2% dextrose [pH 7.5]), containing 50 mM CaCl2. Sporulation medium was prepared as described by
Klapholz and Esposito (31) except that
p-aminobenzoic acid was omitted from the supplement mix.
Chemical mutagenesis of whole yeast cells.
Cells (5 × 107; 5 optical density at 600 nm [OD600]
units) were taken from a culture of budding yeast strain SF838-1D grown to saturation (~7.6 OD600 units/ml) and resuspended in
1.0 ml of phosphate-buffered saline (PBS), and 30 µl of ethyl
methanesulfonate was added as a chemical mutagen (33). The
culture was incubated at 30°C for 1 h. After incubation, an
equal volume of 10% sodium thiosulfate
(Na2S2O3) was added for 10 min to
quench the mutagen and the cells were harvested by centrifugation.
Cells were washed twice with 5%
Na2S2O3 to ensure effective
quenching and removal of the mutagen and then transferred to 30 ml of
YEPD, pH 5, and incubated at 30°C for 24 h to allow recovery.
This treatment resulted in 50 to 60% killing of the cells.
Enrichment and selection for cells showing a Vma
phenotype.
Cells (5 × 107) were allowed to
recover from mutagenesis and then incubated in 10 ml of YEP (yeast
extract-peptone) containing 3% glycerol and 2% ethanol for 16 h
to allow vma mutants to increase in density (46).
Four OD600 units of the culture was carefully layered on a
95% isosmotic Percoll solution, centrifuged at 30,000 × g for 10 min, and then collected in 1-ml fractions,
beginning from the top of the gradient (47).
Screening for the presence of the Vma
phenotype.
Samples (~10% of total) from fractions 5 to 8 of a
population of chemically mutagenized cells fractionated as described
above were plated on YEPD, pH 5, at a concentration giving ~500 to
700 colonies per plate and incubated at 30°C until colonies
developed. Approximately 25,000 colonies were then replica plated
sequentially onto (i) SD (synthetic minimal medium containing 2%
dextrose), (ii) YEPD at pH 7.5, (iii) YEPD containing 100 mM
CaCl2, and (iv) YEPD at pH 5. Replica plates were incubated
at 30°C for 24 h and then scored. Colonies that were unable to
grow on plates 1, 2, and 3 but were able to grow on plate 4 were
selected as Vma
, retested, and then further screened for
complementation of known vma mutants and quinacrine
accumulation.
Complementation testing.
Where necessary, yeast mating type
switching was performed as described previously (18). In
order to assign the new vma mutants to complementation
groups, yeast cells of opposite mating types were patched together on
YEPD (pH 5) plates and incubated for 10 to 14 h to allow mating to
occur. The patches were then replica plated onto pH 7.5, pH 5, or
CaCl2-containing YEPD as described above. Complementation
was indicated by production of a diploid able to grow on YEPD buffered
to pH 7.5 or containing 100 mM CaCl2.
The MEY69 mutant strain, containing the vma45-1 mutation,
was backcrossed twice to wild-type haploid strain CJRY20-3B to help eliminate background mutations resulting from the mutagenesis. The
resulting diploid (YOY69) was sporulated, and the Vma
haploid spore (YOY69-1Ca) was used for cloning of the VMA45 gene and subsequent biochemical analysis.
Cloning and subcloning of the VMA45 gene.
The
yeast genomic library constructed by Scott Houtteman, University of
Chicago, was obtained from Saul Honigberg at Syracuse University. The
library was made by cloning a yeast partial Sau3A genomic
DNA into the BamHI site of YCp50 and has an average insert size of 9 kb. Yeast transformation was performed as described previously (49). The VMA45 gene was cloned by
complementation of the pH-dependent growth phenotypes of yeast strain
YOY69-1Ca. Transformants were plated on supplemented minimal
medium lacking uracil (SD
ura) buffered to pH 7.5 in order to select
transformants that had acquired a URA3-containing plasmid
capable of complementing the Vma
growth phenotype.
Plasmids were isolated from transformants capable of growth on SD
ura
(pH 7.5) plates as previously described (61) and
retransformed into YOY69-1Ca to confirm the phenotype. The
complementing fragment from plasmid pMEY69-1 was further isolated by
subcloning fragments into pRS316 (59) as shown in Fig. 3 and
checking for complementation. All DNA manipulations were done as
described by Sambrook et al. (55).
Disruption of the KEX2 gene.
A null
kex2 strain was constructed by the one-step allele
replacement method (54). The 1,056-bp
AgeI-HpaI fragment within the KEX2
open reading frame (ORF) in plasmid pYO19 (see Fig. 3B) was replaced by
a 2.1-kb HpaI fragment containing the LEU2 gene. The resulting plasmid, pYO53, was digested with XhoI and
NotI to release the LEU2-disrupted allele from
the vector, and the linear DNA fragment generated was used to transform
yeast strain SF838-5Aa. Leu+ transformants were
selected, and disruption of the KEX2 locus was confirmed by
PCR from chromosomal DNA with oligonucleotides 5'-CGACCACATATTATCTGTCCA-3' and
5'-GGATTCTAATGTCTCTTCCGT-3'. Isolation of yeast DNA for PCR
analysis was carried out as described by Nasmyth and Reed
(41) except that DNA was treated with RNase A for 25 min at
37°C and 5 min at 65°C before the final ethanol precipitation.
DNA sequencing.
Plasmid DNA for sequencing was purified with
a QIAprep-spin plasmid kit from Qiagen. Sequencing was done by the
dideoxy chain termination method (56) with a Sequenase
sequencing kit and Sequenase version 2.0 enzyme (United States
Biochemical) and 35S-dATP. Oligonucleotides corresponding
to the T3 and T7 promoter sequences in pRS316 were used as primers.
Tetrad analysis.
Haploid yeast strain YOY69-1A
carrying
the KEX2 gene on a plasmid (pYO19) was mated with haploid
strain SF838-5Aa kex2-
1 on YEPD (pH 5) plates. The
resulting diploid strain (YOY11/pYO19) was selected on supplemented
minimal medium lacking both uracil and leucine. Diploids pregrown
on YEPD, pH 5, for 24 to 30 h were plated on sporulation medium
and incubated at 30°C for 5 days. Tetrads were dissected on YEPD, pH
5, plates. Colonies of germinating spores became visible in less than 2 days. To select for loss of plasmid pYO19, Ura+ spores were
grown nonselectively on YEPD, pH 5, after which uracil auxotrophs were
identified.
Quinacrine vital staining.
Vacuolar accumulation of
quinacrine was assessed as described by Roberts et al. (52).
Once stained, cells were visualized within 10 min with a Zeiss Axioskop
Routine immunofluorescence microscope. Cells were viewed under Nomarski
optics to observe normal cell morphology and under a fluorescein
isothiocyanate filter with a 100× objective to observe vacuolar
staining with quinacrine.
Western blotting.
Whole-cell lysates and solubilized
vacuolar membrane vesicles were prepared, and sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed as
previously described (29). Immunoblots were probed with
monoclonal antibodies 10D7, 7D5, 13D11, and 7A2 and polyclonal
anti-27-kDa-subunit antisera against, respectively, the 100-, 69-, 60-, 42-, and 27-kDa subunits of yeast V-ATPase (22, 29).
Purification of yeast V-ATPase.
Solubilization of vesicles
and purification of V-ATPase were performed basically as described
previously (27, 65) with the following modifications. Four
hundred micrograms of solubilized vesicles were layered on a 12-ml 20 to 50% (vol/vol) glycerol gradient and centrifuged at 200,000 × g for 8 h in a Beckman Ti-75 rotor. Sixteen 700-µl
fractions were collected and analyzed for ATPase activity in order to
identify the peak fractions. Fractions were diluted 1:1 with water, and
protein was precipitated by addition of an equal volume of 20%
trichloroacetic acid. Precipitated proteins were solubilized in 50 µl
of cracking buffer (50 mM Tris-HCl [pH 6.8], 1 mM EDTA, 8 M urea, 5%
SDS, 5%
-mercaptoethanol), separated on an SDS-10% polyacrylamide
gel, and detected by silver staining (67).
Proton pumping.
Proton pumping activity was measured by
monitoring quinacrine fluorescence quenching in an SLM
spectrofluorimeter as described previously (30) with minor
modifications. Briefly, vacuolar membrane vesicles (30 to 40 µg)
suspended in proton transport buffer (15 mM MES-Tris [pH 7.0], 4.8%
glycerol) were added to proton transport buffer containing 7 µM
quinacrine, 2.5 mM MgSO4, 66 mM KCl, and 0.25 µM
valinomycin in a total volume of 1 ml. The mixture was allowed to
equilibrate for 2 min. Proton pumping was initiated by the addition of
ATP to give a final concentration of 2.5 mM. Quinacrine quenching was
monitored at room temperature for 10 min with excitation and emission
wavelengths of 420 and 490 nm, respectively. Under our experimental
conditions, the initial rate of fluorescence quenching was very rapid.
As a result, it was difficult to measure a true initial rate, so the
extents of quenching were compared after the first 15 s. Readings
were normalized relative to the total change in quinacrine fluorescence
in the presence or absence of vesicles.
Other methods.
Monoclonal antibody 13D11 (against the 60-kDa
subunit) was used to coprecipitate the V-ATPase complex as previously
described (26) with the following modifications. In order to
optimize association of the 38-kDa protein (see below) with V-ATPase in kex2 mutants, 2% n-octylglucoside was
substituted for 1% C12E9 and 2 mM (final
concentration) benzamidine was added to the protease inhibitor mixture.
As described previously, all samples contained 0.67 mM
dithiobis(succinimydylpropionate) as a cross-linking agent. For
pulse-chase experiments, spheroplasts were labeled for 5 min (pulse),
unlabeled methionine and cysteine were each added to a final
concentration of 50 µg/ml, and the incubation was continued for
varied times (chase). For samples with no chase, then, unlabeled methionine and cysteine were added immediately before the spheroplasts were harvested. Isolation of vacuolar vesicles was performed as described previously (52). The protein concentration was
determined by the method of Lowry et al. (37). ATPase
activity was measured in a coupled enzyme assay as described previously
(36).
 |
RESULTS |
Genetic screen for vma mutants.
Ohya et al. have
demonstrated that vma mutant cells do not continue to divide
in medium containing a nonfermentable carbon source even though they
continue to synthesize protein and grow in size (46). As a
result, these cells become substantially larger and denser than
wild-type cells upon incubation in medium containing nonfermentable
carbon sources such as glycerol and ethanol. This phenotype was used to
develop an enrichment procedure for Vma
strains based on
density selection by Percoll density gradient centrifugation. As
demonstrated in Fig. 1, two different
Vma
strains (SF838-1D
vma2
::LEU2 and SF838-1D
vma3
::URA3) could be separated from
a mixture containing a ninefold excess of the congenic wild-type strain
by this procedure. Wild-type cells remained near the top of the
gradient, but both types of vma mutant cells peaked in
fractions 5 to 8. Although other mutations in a population of
mutagenized cells may also cause an increase in cell density, Fig. 1
indicates that density fractionation can potentially enrich for
vma mutants in a mutagenized population.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Density selection for vma mutants. Wild-type
yeast strain SF838-1D and two previously identified vma
mutants (SF838-1D vma2 ::LEU2 and
SF838-1D vma3 ::URA3) were
cultured (separately) to log phase in YEPD, pH 5.0. Cells were then
transferred to YEP containing 3% glycerol and 2% ethanol and
incubated at 30°C for 16 h. Wild-type, vma2 , and
vma3 cells were mixed together in the ratio 18:1:1,
respectively, to give a total of 108 cells. The mixed
culture was washed once with size selection buffer (0.67 g of yeast
nitrogen base per liter, 0.25 M sorbitol, 10 mM Tris-HCl [pH 7.5])
and resuspended in 500 µl of the same buffer. Two hundred microliters
(4 × 107 cells) was carefully layered on 10 ml of a
95% isosmotic Percoll solution and centrifuged at 30,000 × g for 10 min. The percentage of wild-type cells ( ) and
vma mutant cells ( ) present in each fraction was
evaluated by plating a sample from each fraction on YEPD, pH 5.0, and
then replica plating the samples to appropriate selective media in
order to identify the percentages of Ura+ and
Leu+ colonies (representing the vma mutants).
Fractions were collected as 1-ml aliquots, beginning from the top of
the gradient. The density gradient is indicated by the dashed line.
Relative density of each fraction was measured with a handheld
refractometer.
|
|
Haploid yeast strain SF838-1D
was chemically mutagenized with
ethyl methanesulfonate as described in Materials and Methods. The
mutagenized cells were allowed to recover in YEPD, pH 5.0, and then
transferred to medium containing the nonfermentable carbon sources
glycerol and ethanol in order to allow any vma mutants to
increase in density. The mutagenized cells were then fractionated on a
Percoll gradient similar to that shown in Fig. 1, and fractions 5 to 8 were analyzed further for the presence of mutants exhibiting Vma
growth phenotypes, including the inability to grow in
medium buffered at pH 7 or above, in medium containing 100 mM
CaCl2, or in medium containing a nonfermentable carbon
source. From an initial collection of over 25,000 colonies, 98 potential Vma
strains were identified. After two more
rounds of screening and loss of some mutants by reversion, 52 mutants
were tested for complementation of existing Vma
strains.
Two vma1 alleles, one vma3 allele, one
vma4 allele, and one vma12 allele were identified
in the collection of mutants. The remaining mutants were tested for the
ability to accumulate quinacrine in the vacuole as a measure of
vacuolar acidification. All known vma mutants are unable to
accumulate the fluorescent weak base quinacrine into their vacuoles due
to loss of acidification (22, 69). Of the 47 mutants tested,
five completely failed to accumulate quinacrine in their vacuoles and
were selected for further studies. (A number of other mutants exhibited
partially defective quinacrine uptake.) Complementation testing was
performed by crossing each of the five mutants with the others and
indicated that the five mutants represent five different
complementation groups, which we designated vma41 to
-45. Three of the new mutant strains (MEY69, MEY32, and
MEY14, containing the vma45-1, vma43-1, and
vma41-1 mutations, respectively) were backcrossed to
CJRY20-3B
or CJRY20-4Ba, and Vma
spores
obtained from sporulation of the resulting diploids, identified by the
inability to grow on YEPD, pH 7.5 (Fig.
2), were selected for further
characterization. In all cases, the Vma
phenotype
segregated 2:2.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 2.
Growth phenotypes of wild-type and vma cells.
Cells were streaked on the medium indicated and incubated at 30°C for
2 days. The vma45 strain is YOY69-1Ca, and the
vma41 and vma43 strains represent
Vma spores derived from a single backcross of the
original mutants. The wild-type strain is SF838-1D , and the
vma12-1 strain represents a new allele of VMA12
identified in the screen described here.
|
|
In order to examine the stability of several known subunits of V-ATPase
in the mutant strains, whole-cell protein extracts were prepared and
analyzed by Western blotting with antibodies against five different
V1 (peripheral) subunits of V-ATPase, Vma1p, Vma2p, Vma4p,
Vma5p, and Vma13p, and the V-ATPase assembly protein Vma12p (21,
22, 69). All these proteins appeared to be present at wild-type
levels in the mutant cells (data not shown), indicating that the
steady-state levels of these polypeptides are not affected in the new
vma mutants.
Cloning of the VMA45 gene.
The wild-type
VMA45 gene was cloned by complementation of the pH-dependent
growth phenotype of the haploid yeast strain YOY69-1Ca containing the vma45-1 allele. YOY69-1Ca mutant
cells were transformed with a yeast genomic library carried on the
yeast low-copy-number plasmid YCp50 and plated directly on SD
ura
buffered at pH 7.5 to select for those transformants bearing plasmids
able to restore growth at pH 7.5 to the mutant cells. Of an estimated 35,000 Ura+ transformants, 10 were found to be
Ura+ Vma+, and 6 of these contained the same
plasmid, pMEY69-1. Of the remaining four transformants, three contained
the same plasmid, pMEY69-5, and one contained plasmid pMEY69-7.
Complementation for the vma phenotypes of the
vma45-1 strain was plasmid dependent; pMEY69-1 fully
complemented the growth phenotypes of the mutant strain, while plasmids
pMEY69-5 and pMEY69-7 gave only partial complementation (data not
shown).
Plasmid pMEY69-1, which gave the best complementation of the
vma45-1 mutant growth phenotype, contained a 6.5-kb insert
and was mapped as shown in Fig. 3A.
Several different subclones were generated in the yeast shuttle vector
pRS316 and tested for complementation. As shown in Fig. 3, a 3.3-kb
EcoRI fragment (pYO19) of the insert was sufficient for
complementation. A 480-bp region internal to this fragment was
sequenced and used to search for homology to any sequences in the
GenBank and EMBL databases. The sequence comparison (data not shown)
indicated identity to the yeast KEX2 gene, which encodes a
neutral serine protease localized to the late Golgi compartment
(51), covering the entire sequenced region of
VMA45. Comparison of the restriction maps of KEX2
and pYO19 also revealed a perfect match (Fig. 3A) but indicated that
pYO19 lacked 300 bp from the C terminus of the KEX2 ORF.
Previous reports of cloning of the KEX2 gene had also
indicated that this fragment could fully complement a number of
kex2 mutant phenotypes (24, 34). Restriction
mapping of pMEY69-5 and pMEY69-7 indicated no overlap with pMEY69-1 or
between the two plasmids.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 3.
(A) Restriction map of pMEY69-1 and various subclones.
Restriction endonuclease sites are indicated. B, BamHI; C,
ClaI; E, EcoRI; H, HindIII; Rv,
EcoRV; S, SalI; X, XbaI. The fragments
indicated were subcloned into pRS316 to give the plasmids indicated at
the right and then tested for complementation of the Vma
growth phenotypes of YOY69-1Ca. The hatched box represents
the complementing subclone, and arrows indicate the direction and
extent of sequence determination. The KEX2 gene is shown as
stippled box. (B) Disruption of the KEX2 gene. A 1,056-bp
AgeI-HpaI fragment within the KEX2 ORF
was replaced with a 2.2-kb fragment containing the LEU2
gene.
|
|
A LEU2-disrupted copy of the KEX2 gene was
constructed (Fig. 3B), and the chromosomal KEX2 locus was
disrupted by a one-step gene replacement method (54).
Disruption of the KEX2 gene was confirmed by PCR analysis of
genomic DNA.
kex2-
1 mutants display Vma
phenotypes.
Previous studies have indicated that kex2
mutants display pleiotropic phenotypes (5, 32, 34) but
failed to indicate any link to vacuolar acidification. Similarly,
previous studies of yeast V-ATPase did not suggest an interaction with
the Kex2p endoprotease or any other protease. We therefore addressed
first the issue of whether there was any overlap between the previously described growth phenotypes of kex2 and vma
mutants. All vma mutants, except for vph1
and
stv1
single mutants (38, 39), have been shown
to grow more slowly than wild-type cells in unbuffered YEPD and to show
no growth on YEPD buffered to pH 7.5, YEPD containing 4 mM
ZnCl2, or YEP containing glycerol and ethanol as the sole carbon sources (39, 43, 46, 69). As shown in Table
2, the Vma
growth
phenotypes of the vma45-1 and kex2-
1 mutants
were identical to those of the vma3
mutant strain.
kex2 null mutants have been reported to be cold sensitive
(32, 40), so we tested whether vma mutants were
also cold sensitive. After 72 h on unbuffered YEPD at 17°C, the
vma3
, kex2-
1, and vma45-1 mutant
strains exhibited no growth (Table 2). Interestingly, the
cold-sensitive phenotype of the mutants proved to be pH dependent.
Although all three mutants failed to grow on YEPD at 17°C, they grew
quite well on YEPD, pH 5, plates at 17°C (Table 2). This pH-dependent
cold sensitivity was observed for other vma mutants tested,
strongly suggesting that the cold sensitivity of kex2 is a
Vma
phenotype. Two multicopy suppressors of the
cold-sensitive phenotype and
-factor processing defect of
kex2 null mutants, YAP3 and MKC7, have
been identified (32). In order to determine whether these
genes can also rescue the Vma
growth phenotypes of
kex2 mutants, kex2-
1 cells were transformed with the YAP3 or MKC7 gene on a multicopy plasmid
(2µm) and the transformants were tested for pH-sensitive growth. The
results are shown in Fig. 4. As described
above, the kex2-
1 mutants could not grow on SD
ura
plates buffered to pH 7.0 (Fig. 4, right plate, top left quadrant).
This pH-dependent growth defect was fully complemented by the pYO19
plasmid (top right quadrant), suppressed quite well by
2µm-MKC7 (lower right quadrant), and weakly suppressed by
2µm-YAP3 (lower left quadrant). 2µm-MKC7 also
partially suppressed the growth defect of kex2-
1 cells at
pH 7.5, but the 2µm-YAP3 transformants could not grow
under these conditions. These results indicate that YAP3 and
MKC7 are multicopy suppressors of the Vma
growth phenotypes of kex2 mutants. MKC7 appears
to be a stronger suppressor of the pH-sensitive growth phenotype than
YAP3; Komano and Fuller (32) found that
MKC7 also suppressed the cold sensitivity of kex2
mutants more effectively than YAP3.

View larger version (93K):
[in this window]
[in a new window]
|
FIG. 4.
Multicopy MKC7 and YAP3 suppress
the growth defects of kex2- 1 mutants at pH 7.0. SF838-5Aa kex2 mutant cells were transformed with
pYO19 (wild-type KEX2 on a low-copy-number plasmid),
MKC7 on a 2µm plasmid, YAP3 on a 2µm plasmid,
or YEp24 (the 2µm plasmid with no insert). Transformants were
initially identified by growth on unbuffered SD ura (pH approximately
5.7) and then streaked to unbuffered SD ura (left plate) and grown for
3 days at 30°C or to SD ura buffered to pH 7.0 (right plate) and
grown for 5 days at 30°C. Growth of kex2- 1 cells
transformed with the following plasmids is shown (clockwise from top):
pYO19, 2µm-MKC7, 2µm-YAP3, and YEp24.
|
|
Our initial characterization of the vma45-1 mutant strain
indicated that it was unable to accumulate quinacrine in the vacuole. In order to test whether kex2-
1 cells are able to acidify
their vacuoles, we examined quinacrine uptake in these cells. Our
results, shown in Fig. 5, indicate that,
like the vma45-1 mutant strain YOY69-1Ca,
kex2
cells do not accumulate quinacrine and thus appear
to be defective in vacuolar acidification. Together, these results
demonstrate that kex2
mutants behave as true
vma mutants.

View larger version (73K):
[in this window]
[in a new window]
|
FIG. 5.
Loss of vacuolar acidification in kex2
mutants. Vacuolar acidification was assessed by quinacrine accumulation
in the vacuole as described in Materials and Methods. Log-phase yeast
cells were incubated in 500 µl of PBS, pH 7, containing 200 µM
quinacrine for 5 min at 30°C. After being stained, cells were washed
with 500 µl of PBS and resuspended in 100 µl of the same buffer.
Cells were viewed with differential interference contrast optics for
observation of normal cell morphology and by fluorescence microscopy
with a fluorescein isothiocyanate filter for observation of vacuolar
staining with quinacrine. Each monograph is a composite of three to
four fields. The following strains were used: SF838-5Aa
(wild type), SF838-5Aa kex2- 1 (kex2 ),
and YOY69-1Ca (vma45).
|
|
Both the Vma
growth phenotypes and the loss of vacuolar
quinacrine staining in the kex2-
1 mutant were fully
rescued by the plasmids pMEY69-1 and pYO19. These plasmids restored
normal, pH-independent growth to the vma45-1 mutant strain
YOY69-1Ca but failed to fully restore quinacrine staining to
this mutant (data not shown). Plasmids pMEY69-5 and pMEY69-7, which
gave partial complementation of the vma45-1 growth
phenotype, did not complement the kex2
mutant phenotypes.
These results indicate that vma45-1 is probably not a null
mutant and that the pMEY69-5 and pMEY69-7 plasmids behave as
allele-specific suppressors.
VMA45 is allelic to KEX2.
To confirm that
vma45-1 is indeed a mutant allele of KEX2,
haploid strain MEY69-1A
, carrying a plasmid-borne copy of the wild-type KEX2 gene (pYO19), was mated to SF838-5Aa
kex2
::LEU2 to give diploid strain
YOY11/pYO19. Since kex2 mutants are
-specifically sterile
(34) and we had also observed that MEY69-1A
appears to be
sterile, it was necessary to introduce a plasmid-borne KEX2 gene into MEY69-1A
before the mutants were mated. When the YOY11 diploid cells were cured of the pYO19 plasmid, they became unable to
grow on YEPD (pH 7.5) plates, indicating that the kex2-
1
mutant is unable to complement the vma growth phenotypes of
the vma45-1 mutant strain. When YOY11 diploid cells lacking
the pYO19 plasmid were patched on sporulation medium and incubated at
30°C, no tetrads were detected even after 2 weeks, in agreement with
previous results showing that kex2 homozygous diploids are
deficient in sporulation (34). YOY11/pYO19 cells were able
to sporulate, tetrads were dissected after 5 days on sporulation
medium, and the spores were allowed to germinate on YEPD, pH 5. Tetrad
analysis suggested a 4:0 segregation of the Vma
phenotype, since all Ura
spores are Vma
and
all Ura+ spores are Vma+. To confirm these
results, four Ura+ spores from two different tetrads were
cured of the plasmid. In all cases, Ura
colonies became
Vma
, confirming that the Vma
phenotype
segregates 4:0 in YOY11.
Characterization of V-ATPase from kex2-
1 cells.
Western blot analysis of whole-cell lysates showed that the
steady-state levels of several V-ATPase subunits are not affected in
the vma45-1 mutant (see above). Similar experiments were
performed to determine the levels of several subunits of the V-ATPase
in kex2-
1 cells. Immunoblot analysis revealed that the
levels and apparent molecular masses of the 69-, 60-, 54-, 42-, and
27-kDa V1 subunits were not altered in whole-cell lysates
from the kex2-
1 cells relative to those of the wild type.
Similarly, 25-kDa Vma12p, implicated in the assembly of V-ATPase, did
not appear to be affected in these cells (data not shown).
A number of mutants that contain near-normal cellular levels of
V-ATPase subunits show little or no assembly of the ATPase complex
(6). We examined the assembly of V-ATPase in
kex2-
1 mutant cells by immunoprecipitating the ATPase
complex under nondenaturing conditions (6, 26). Cells were
converted to spheroplasts and then biosynthetically labeled with
Tran35S-label for 5 min in order to examine the early steps
in assembly of the complex or for 60 min in order to examine the final
assembled complex. Immunoprecipitations were carried out with a
monoclonal antibody against the 60-kDa V1 subunit of ATPase
(13D11). This antibody recognizes the 60-kDa V1 subunit by
itself, as part of a V1 subcomplex or as part of a fully
assembled V1V0 complex, and can therefore
coprecipitate the whole V-ATPase complex under nondenaturing
conditions. Coimmunoprecipitated proteins were separated by SDS-PAGE
and detected by autoradiography. Comparison of immunoprecipitated proteins from the 60-min labeling experiments whose results are shown
in Fig. 6B (60-min pulse, 0-min chase)
indicates that all of the previously identified subunits of the yeast
V-ATPase that are immunoprecipitated from the wild-type cells are also
immunoprecipitated from the kex2-
1 cells, suggesting that
the mutant cells do not have an assembly defect. Similarly, there does
not appear to be any drastic difference in the kinetics of assembly for
the two strains, based on the 5-min pulse and 0-min chase, 5-min pulse and 5-min chase, and 5-min pulse and 15-min chase samples (Fig. 6A).
One detectable difference was the presence of an extra protein band of
~38 kDa (Fig. 6) which is coprecipitated with the V-ATPase from
kex2-
1 cells. This band had a relative mobility between those of the previously identified 42- and 36-kDa subunits of V-ATPase.
The 38-kDa band is also coimmunoprecipitated with V-ATPase in
vma45-1 mutant cells (data not shown). In addition, a
protein with a relative molecular mass between 17 and 27 kDa also
appears to be specifically coprecipitated from kex2
cells.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 6.
Assembly of V-ATPase in wild-type and kex2
mutant cells. Nondenaturing immunoprecipitation of V-ATPase from
biosynthetically labeled yeast cells was performed as described
previously (34). Monoclonal antibody 13D11 against the
60-kDa peripheral V1 subunit was used for
immunoprecipitation. Immunoprecipitated proteins were separated by
SDS-PAGE and visualized by autoradiography. The positions of previously
identified subunits of V-ATPase are indicated. The arrow indicates the
38-kDa band that is present in kex2 mutant strains but
not in wild-type strains. Positions of protein molecular mass standards
are indicated on the left. The strains used are the same as those used
in the experiment shown in Fig. 5. (A) Steps in V-ATPase assembly
(5-min pulse, varied chase times); (B) final assembled V-ATPase complex
(60-min pulse, 0-min chase).
|
|
In order to address the vacuolar targeting and catalytic activity of
V-ATPase in the kex2-
1 mutant cells, vacuolar vesicles were isolated from the kex2-
1 mutant cells and the
congenic wild-type strain. The concanamycin A-sensitive ATPase
activities in the isolated vacuolar membranes are compared in Table
3. Concanamycin A is a very potent and
specific inhibitor of V-ATPases (8). As shown in Table 3,
vacuolar vesicles from kex2-
1 cells have the same level
of V-ATPase activity as that of the vesicles from wild-type cells in
vitro, even though the growth phenotypes and lack of quinacrine
accumulation strongly suggest that V-ATPase is not active in vivo.
Proton pumping activity of vacuolar membrane vesicles was also measured
by examining the Mg-ATP-dependent quenching of quinacrine fluorescence
in the isolated vesicles (Table 3). The vesicles isolated from
kex2-
1 cells showed an initial rate and extent of
quinacrine quenching similar to or somewhat greater than those of
wild-type vesicles (Table 3), indicating that ATP hydrolysis and proton
pumping have not been uncoupled in the kex2-
1 mutant.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
V-ATPase and proton pumping activities of vacuolar
membrane vesicles isolated from wild-type and
kex2- 1 cells
|
|
We investigated whether there was a structural defect in V-ATPase in
kex2-
1 mutant vacuoles (for example, altered subunit stoichiometry or the presence of extra inhibitory proteins) by two
different approaches. First, the levels of various subunits in isolated
vacuolar membrane vesicles were analyzed by Western blotting with
antibodies against the 100-kDa integral membrane subunit and the 69-, 60-, 42-, and 27-kDa peripheral subunits of V-ATPase. As shown in Fig.
7A, all of the V-ATPase subunits monitored are present in kex2-
1 vacuolar membranes at
levels similar to those of the wild type. Second, we solubilized
vacuolar membrane vesicles and purified V-ATPase by glycerol gradient
centrifugation (28, 65). ATPase activities fractionated to
similar positions in gradients of the wild-type and mutant vacuolar
membranes. Proteins from the fractions with peak V-ATPase activities
were separated by SDS-PAGE and detected by silver staining. As shown in
Fig. 7B, the subunit composition of the V-ATPase isolated from
kex2-
1 mutant cells is indistinguishable from that of the
V-ATPase from wild-type cells.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 7.
V-ATPase isolated from kex2- 1 vacuolar
membranes is indistinguishable from that isolated from the wild type.
(A) Vacuolar membrane vesicles were incubated in cracking buffer (50 mM
Tris-HCl [pH 6.8], 8 M Urea, 1 mM EDTA, 5% SDS, 5%
-mercaptoethanol) for 20 min at 50°C for the 100-kDa
V0 subunit or 70°C for the remaining subunits. Fifteen
micrograms (for detection of the 100-kDa subunit) or 3 µg (for
detection of all other subunits) of vacuolar protein was loaded in each
lane. Proteins were detected on Western blots with alkaline
phosphatase-conjugated antibodies. (B) V-ATPase was purified from
vacuolar membrane vesicles as described in Materials and Methods.
Proteins in fractions with peak ATPase activities were separated on an
SDS-10% polyacrylamide gel and visualized by silver staining.
Positions of known V-ATPase subunits are indicated on the right. The
asterisk indicates the position of an unidentified protein that
consistently copurifies with V-ATPase activity. The positions of
protein molecular weight standards (in thousands) are indicated on the
left.
|
|
 |
DISCUSSION |
kex2 mutants exhibit Vma
phenotypes in
vivo but functional V-ATPases in vitro.
We have defined five new
vma complementation groups based on the set of
well-characterized Vma
phenotypes used in previous
screens by using a screening process that contains an initial step
designed to enrich for vma mutants based on density
differences following growth on a nonfermentable carbon source. The
Vma
growth defects, including pH-dependent growth
(43, 69), Ca2+ sensitivity (46),
Zn2+ sensitivity (3), and inability to utilize
nonfermentable carbon sources (46), have proven to be highly
diagnostic of defects in V-ATPase activity, particularly when these
defects are combined with a loss of vacuolar acidification assessed
with lysosomotropic dyes. With the exception of the vph1
mutant (38), mutants lacking each of the 13 cloned subunits
of V-ATPase exhibit the full set of Vma
growth defects as
well as a loss of vacuolar acidification (references 2 and 15 and references therein;
see also references 27 and 63).
Several other mutants that exhibit Vma
growth phenotypes
have subsequently been shown to affect genes that do not encode
subunits of V-ATPase but that are nevertheless essential for the
assembly and/or activity of the enzyme (VMA12 or
VPH2 [2, 21], VMA21
[19], VMA22 [20], and
VPH6 [17]). Furthermore, analysis of point
mutations causing partial defects in V-ATPase activity (35)
has demonstrated that the onset of the pH-dependent growth phenotype
requires the loss of at least 75% of V-ATPase activity at the vacuole.
Therefore, the growth phenotypes and lack of quinacrine accumulation in
the new mutants reported here, and particularly in the
vma45-1 and kex2-
1 mutants, indicate that
V-ATPase activity is seriously compromised in these mutants in vivo.
In this study, we have focused on the new vma45-1 allele
generated in our mutant screen, demonstrated by a number of criteria that it is a mutant allele of the previously characterized
KEX2 gene, and compared the genetic and biochemical
characteristics of the vma45-1 strains with those of a
kex2-
1 mutant strain. All of the data indicate that a
functional Kex2 protein is essential for maintaining vacuolar
acidification in vivo. In addition, an essential role for Kex2p in
vacuolar acidification may help explain several of the previously
reported pleiotropic phenotypes of kex2 mutants that could
not be accounted for by the previously characterized functions of Kex2p
(5, 32, 40). We demonstrate here that a vma3
mutant, which lacks the proteolipid subunit of V-ATPase (42), exhibits a similar cold sensitivity to
kex2-
1 mutants and that this cold sensitivity is pH
dependent. Komano and Fuller (32) have demonstrated that the
growth arrest at 16°C of kex2
mutants is accompanied by
aberrant cell morphologies, including formation of multiple buds, actin
and chitin delocalization, and a substantial increase in cell volume.
We have recently found that vma mutants exhibit similar
morphological changes and alterations in actin and chitin
delocalization when they are incubated at elevated pH (71),
suggesting that the morphological defects of the kex2-
1
mutant in YEPD at 16°C may also be linked to its role in vacuolar
acidification. In addition, kex2
strains have been shown
to be hypersensitive to the drug quinidine, a weak base (5).
Since quinidine appears to accumulate in acidic compartments in
wild-type cells (5) and loss of vacuolar acidification would prevent this accumulation, one consequence of vacuolar acidification defects of kex2-
1 mutants might be to increase the
effective concentration of quinidine in cytoplasm, resulting in
hypersensitivity.
Despite the evidence that Kex2p is essential for normal vacuolar
acidification, the data also present a paradox. All of the other
mutants expressing a Vma
phenotype that have been
analyzed also show defects in V-ATPase activity in vitro, in purified
vacuoles, and/or in the purified enzyme complex. In contrast, assembly
of the V-ATPase complex did not seem to be affected significantly in
kex2-
1 mutants (Fig. 6), isolated vacuolar vesicles
from kex2
cells contained levels of V-ATPase and proton
pumping activity comparable to those of vesicles from wild-type cells
(Table 3), and the purified V-ATPase complex from a
kex2-
1 mutant showed no obvious structural differences from the wild-type complex (Fig. 7). These results suggest that the
effects of kex2 mutations on the V-ATPase are exerted in the intact cell and that the ATPase is present in the mutant strain in a
fully assembled state, potentially capable of hydrolyzing ATP. This is
the first time that a mutation which confers the characteristic
Vma
phenotypes in vivo but has no effect on the assembly
or in vitro activity of V-ATPase has been identified. It is possible
that a factor required for in vivo but not in vitro activity of
V-ATPase is missing or defective in the kex2
mutant.
How might Kex2p regulate vacuolar acidification in vivo?
Based
on the data shown here, it is possible that Kex2p plays a positive role
in regulating vacuolar acidification or V-ATPase activity in vivo. It
is not clear how V-ATPases are regulated in any system, and the
available data indicate that multiple mechanisms are probably important
in regulating activity (reviewed in reference 10).
The yeast KEX2 gene product was first identified as the endopeptidase required for the processing of yeast prepro-
-factor and K1 killer toxin (25, 34). Kex2p is a highly conserved serine endoprotease localized to the late Golgi compartment (11, 51) that specifically cleaves proprotein substrates on the
carboxyl sides of pairs of basic residues (preferentially -Lys-Arg- and -Arg-Arg-; reviewed in reference 12). Pleiotropic
phenotypes of kex2 mutant strains suggest that other
substrates have yet to be identified (5, 32, 40).
There are several potential models that may explain how Kex2p activity
might be involved in regulation of vacuolar acidification in vivo
without apparently affecting the in vitro activity of yeast V-ATPase.
An explanation that is consistent with our data is that Kex2p might
activate V-ATPase by processing a negative regulator of the enzyme
(protein X). In such a model, protein X would be assembled initially as
part of a V-ATPase (sub)complex and would inhibit any activity of the
enzyme. It would then be removed in wild-type cells as a result of
Kex2p processing in the late Golgi compartment. In this model, the
V-ATPase would be activated in the Golgi apparatus; the site of
activation would be the point at which Kex2p is localized and the
earliest point at which organellar acidification is detected
(1). In the absence of a functional Kex2p, V-ATPase would be
assembled with protein X, protein X would not be processed, and the
enzyme would be transported in a nonfunctional form to the vacuole. If
protein X is loosely associated with the V-ATPase, our lysis conditions
are not optimal for the association, or if other proteases active when
cells are disrupted can replace Kex2p in processing, protein X might
easily be lost during the process of cell lysis and vacuolar isolation, thus giving rise to a fully active V-ATPase in vitro.
This model is speculative, but several pieces of data lend it
credibility. The experiment shown in Fig. 6, in which an extra 38-kDa
protein band was seen to be associated with the V-ATPase from
kex2-
1 cells, supports the model, although further
experiments will be necessary to address directly whether this protein
is a Kex2p substrate and a V-ATPase inhibitor. The protein of
approximately 20 kDa that is coprecipitated from kex2
cells in Fig. 6 is also a candidate for an ATPase inhibitor, but this
protein is also present in active, gradient-purified, V-ATPase from
kex2
cells (Fig. 7), suggesting that it is not an
inhibitor. Studies of V-ATPase from bovine chromaffin granules and
kidney microsomes (62) indicated the presence of an
accessory subunit (Ac45) in the V0 sector of the enzyme,
which appears to undergo posttranslational proteolytic processing. Ac45
was shown to be oriented with the bulk of the protein lying in the
lumen of the vacuolar network (62), and the predicted
lumenal domain contains a dibasic site (-Lys-Lys-) 60 residues from the
C terminus that may potentially be recognized by a mammalian Kex2p
homolog (mammalian Kex2p homologs cleave at -Lys-Lys-
[7]). The Ac45 protein was shown to be present at an
approximately 1:1 stoichiometry with the V-ATPase complex in chromaffin
granules (62), but the specific effects of Ac45 association
on activity of the chromaffin granule ATPase have not been examined. A
search for proteins with sequence homology to Ac45 in the yeast genome
database revealed no obvious candidates, but this finding does not
eliminate the possibility that yeast cells have a functional homolog.
Although the Ac45 protein has not been shown to be an inhibitor of
V-ATPase, specific inhibitors of V-ATPases in bovine kidney microsomes
have been identified (70). Zhang et al. have described a
small (6.3-kDa) inhibitory protein isolated from a cytosolic fraction
that probably acts as a dimer (70). Since this inhibitor is
a cytosolic protein, it seems unlikely that it is a substrate for a
Kex2p-related protease itself, but its action may be regulated
indirectly by a Kex2p-like protease. A small, soluble inhibitor protein
(IF1) has also been identified in evolutionarily related
F-type ATPases from different sources. IF1 was shown to
bind F1F0 in a 1:1 stoichiometry and completely
inhibit enzyme activity (16).
Physiological implications of a role for Kex2p in regulation of
vacuolar acidification.
This is the first report implicating a
protease in regulation of vacuolar acidification and V-ATPase. It is
difficult to demonstrate directly that the protease activity of Kex2p
is essential for its role in vacuolar acidification, because Kex2p
autocatalytic processing appears to be essential for its activity
(13). However, Komano and Fuller have demonstrated that the
cold-sensitive phenotypes of a kex2
mutant can be
suppressed by multiple copies of two other proteases, Mkc7p and Yap3p,
which are also capable of cleaving at clusters of basic residues,
indicating that proteolysis of a single substrate or redundant
substrates is essential for growth on unbuffered YEPD at 16°C
(32). We have demonstrated that kex2-
1 cold
sensitivity is pH dependent and is related to its Vma
phenotypes. Furthermore, we show that the Vma
growth
defects of kex2 mutants can be suppressed by multiple copies
of YAP3 or MKC7. Together, these results indicate
that a substrate essential for vacuolar acidification requires
proteolytic processing.
A role for Kex2p activity in regulation of vacuolar acidification makes
physiological sense for several reasons. As described above, the
localization of Kex2p is well-suited to activation of V-ATPase
activity, since the late Golgi apparatus is the earliest compartment of
the secretory pathway shown to have an acidic pH (1). In
activating V-ATPase in mammalian cells, Kex2p activity, or the
activities of related proteases in other cell types, might serve to
enhance proteolytic activity toward other substrates as well. Yeast
Kex2p has been shown to correctly process prohormones in mammalian
cells (64), indicating that Kex2p activity is highly conserved in evolution. Mammalian prohormone processing is initiated in
the late Golgi or trans-Golgi network, where Kex2p is
localized, and dependent on the action of V-ATPase (68).
Although the function of low pH in prohormone processing has not been
fully characterized, it has been suggested that the processing enzymes
may require either a low pH for optimum activity or a pH-dependent
conformational change in the substrate for recognition and binding
(68). In this context, Kex2p activity seems to be
strategically poised to serve a function in promoting organelle
acidification by V-ATPases, which in turn enhance Kex2p function toward
other substrates.
Future studies will be directed toward further defining the functional
relationships among yeast V-ATPase, vacuolar acidification, and the
Kex2 endoprotease. To this end, we will be particularly interested in
defining the Kex2p substrate that affects vacuolar acidification and in
testing the hypothesis that this substrate inhibits the potentially
active V-ATPase in kex2 mutant cells.
 |
ACKNOWLEDGMENTS |
This work was supported by a National Institutes of Health grant
(R01-GM50322) and an NSF Presidential Young Investigator Award
(MCB-9296244) to P.M.K. P.M.K. is an American Heart Association Established Investigator.
We thank Saul Honigberg (Syracuse University) for the yeast genomic
library, Robert Fuller (University of Michigan) for the YAP3
and MKC7 genes on multicopy plasmids, and Dave Amberg (SUNY Health Science Center, Syracuse) for the use of his microscope.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biochemistry and Molecular Biology, SUNY Health Science Center at
Syracuse, 750 E. Adams St., Syracuse, NY 13210. Phone: (315) 464-8742. Fax: (315) 464-8750. E-mail:
kanepm{at}vax.cs.hscsyr.edu.
 |
REFERENCES |
| 1.
|
Anderson, R. G., and L. Orci.
1988.
A view of acidic intracellular compartments.
J. Cell Biol.
106:539-543[Free Full Text].
|
| 2.
|
Anraku, Y.,
N. Umemoto,
R. Hirata, and Y. Wada.
1989.
Structure and function of the yeast vacuolar membrane proton ATPase.
J. Bioenerg. Biomembr.
21:589-603[Medline].
|
| 3.
|
Bachhawat, A. K.,
M. F. Manolson,
D. G. Murdock,
J. D. Garman, and E. W. Jones.
1993.
The VPH2 gene encodes a 25-kDa protein required for activity of the yeast vacuolar H+-ATPase.
Yeast
9:175-184[Medline].
|
| 4.
|
Bauerle, C.,
M. N. Ho,
M. A. Lindorfer, and T. H. Stevens.
1993.
The Saccharomyces cerevisiae VMA6 gene encodes the 36-kDa subunit of the vacuolar H+-ATPase membrane sector.
J. Biol. Chem.
268:99-102.
|
| 5.
|
Conklin, D. S.,
M. R. Culbertson, and C. Kung.
1994.
Saccharomyces cerevisiae mutants sensitive to the antimalarial and antiarrhythmic drug, quinidine.
FEMS Microbiol. Lett.
119:221-228[Medline].
|
| 6.
|
Doherty, R. D., and P. M. Kane.
1993.
Partial assembly of the yeast vacuolar H+-ATPase in mutants lacking one subunit of the enzyme.
J. Biol. Chem.
268:16845-16851[Abstract/Free Full Text].
|
| 7.
|
Douglass, J.,
O. Civelli, and E. Herbert.
1984.
Polyprotein gene expression: generation of diversity of neuroendocrine peptides.
Annu. Rev. Biochem.
53:665-715[Medline].
|
| 8.
|
Drose, S.,
K. U. Bindseil,
E. J. Bowman,
A. Siebers,
A. Zeeck, and K. Altendorf.
1993.
Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosine triphosphatases.
Biochemistry
32:3902-3906[Medline].
|
| 9.
|
Forgac, M.
1989.
Structure and function of vacuolar class of ATP-driven proton pumps.
Physiol. Rev.
69:765-796[Free Full Text].
|
| 10.
|
Forgac, M.
1996.
Regulation of vacuolar acidification, p. 121-132.
Organellar ion channels and transporters.
The Rockefeller University Press, New York, N.Y.
|
| 11.
|
Fuller, R. S.,
A. J. Brake, and J. Thorner.
1989.
Intracellular targeting and structural conservation of a prohormone processing endoprotease.
Science
246:482-486[Abstract/Free Full Text].
|
| 12.
|
Fuller, R. S.,
R. E. Sterne, and J. Thorner.
1988.
Enzymes required for yeast prohormone processing.
Annu. Rev. Physiol.
50:345-362[Medline].
|
| 13.
|
Gluschankof, P., and R. S. Fuller.
1994.
A C-terminal domain conserved in precursor processing proteases is required for intramolecular N-terminal maturation of pro-kex2 protease.
EMBO J.
13:2280-2288[Medline].
|
| 14.
|
Graham, L. A.,
K. J. Hill, and T. H. Stevens.
1994.
VMA7 encodes a novel 14-kDa subunit of the Saccharomyces cerevisiae vacuolar H+-ATPase complex.
J. Biol. Chem.
269:25974-25977[Abstract/Free Full Text].
|
| 15.
|
Graham, L. A.,
K. J. Hill, and T. H. Stevens.
1995.
VMA8 encodes a 32-kDa V1 subunit of the Saccharomyces cerevisiae vacuolar H+-ATPase required for function and assembly of the enzyme complex.
J. Biol. Chem.
270:15037-15044[Abstract/Free Full Text].
|
| 16.
|
Hashimoto, T.,
Y. Yoshida, and K. Tagawa.
1990.
Regulatory proteins of the F1F0-ATPase: role of ATPase inhibitor.
J. Bioenerg. Biomembr.
22:27-38[Medline].
|
| 17.
|
Hemenway, C. S.,
K. Dolinsky,
M. E. Cardenas,
M. A. Hiller,
E. W. Jones, and J. Hietman.
1995.
vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H+-ATPase assembly.
Genetics
141:833-844[Abstract].
|
| 18.
|
Herskowitz, I., and R. E. Jensen.
1990.
Putting the HO gene to work: practical uses for mating-type switching.
Methods Enzymol.
194:132-146.
|
| 19.
|
Hill, K. J., and T. H. Stevens.
1994.
Vma21p is a yeast membrane protein retained in the endoplasmic reticulum by a di-lysine motif and is required for the assembly of the vacuolar H+-ATPase complex.
Mol. Biol. Cell
5:1039-1050[Abstract].
|
| 20.
|
Hill, K. J., and T. H. Stevens.
1995.
Vma22p is a novel endoplasmic reticulum-associated protein required for assembly of the yeast vacuolar H+-ATPase complex.
J. Biol. Chem.
270:22329-22336[Abstract/Free Full Text].
|
| 21.
|
Hirata, R.,
N. Umemoto,
M. N. Ho,
Y. Ohya,
T. H. Stevens, and Y. Anraku.
1993.
VMA12 is essential for assembly of the vacuolar H+-ATPase subunits onto the vacuolar membrane in Saccharomyces cerevisiae.
J. Biol. Chem.
268:961-967[Abstract/Free Full Text].
|
| 22.
|
Ho, M. N.,
K. J. Hill,
M. A. Lindorfer, and T. H. Stevens.
1993.
Isolation of vacuolar membrane H+-ATPase-deficient yeast mutants: the VMA5 and VMA4 genes are essential for assembly and activity of the vacuolar H+-ATPase.
J. Biol. Chem.
268:221-227[Abstract/Free Full Text].
|
| 23.
|
Ho, M. N.,
R. Hirata,
N. Umemoto,
Y. Ohya,
A. Takatuski,
T. H. Stevens, and Y. Anraku.
1993.
VMA13 encodes a 54-kDa vacuolar H+-ATPase subunit required for activity but not assembly of the enzyme complex in Saccharomyces cerevisiae.
J. Biol. Chem.
268:18286-18292[Abstract/Free Full Text].
|
| 24.
|
Julius, D.,
A. Brake,
L. Blair,
R. Kunisawa, and J. Thorner.
1984.
Isolation of the putative structural gene for the lysine-arginine-cleaving endopeptidase required for processing of yeast prepro- -factor.
Cell
37:1075-1089[Medline].
|
| 25.
|
Julius, D.,
L. Blair,
A. Brake,
G. Sprague, and J. Thorner.
1983.
Yeast -factor is processed from a larger precursor polypeptide: the essential role of a membrane-bound dipeptidyl aminopeptidase.
Cell
32:839-852[Medline].
|
| 26.
|
Kane, P. M.
1995.
Disassembly and reassembly of the yeast vacuolar H+-ATPase in vivo.
J. Biol. Chem.
270:17025-17032[Abstract/Free Full Text].
|
| 27.
|
Kane, P. M., and T. H. Stevens.
1992.
Subunit composition, biosynthesis and assembly of the yeast vacuolar proton-translocating ATPase.
J. Bioenerg. Biomembr.
24:383-393[Medline].
|
| 28.
|
Kane, P. M.,
C. T. Yamashiro, and T. H. Stevens.
1989.
Biochemical characterization of the yeast vacuolar H+-ATPase.
J. Biol. Chem.
264:19236-19244[Abstract/Free Full Text].
|
| 29.
|
Kane, P. M.,
M. C. Kuehn,
I. Howald-Stevenson, and T. H. Stevens.
1992.
Assembly and targeting of peripheral and integral membrane subunits of the yeast vacuolar H+-ATPase.
J. Biol. Chem.
267:447-454[Abstract/Free Full Text].
|
| 30.
|
Kibak, H.,
D. VanEeckhout,
T. Cutler,
S. L. Taiz, and L. Taiz.
1993.
Sulfite both stimulates and inhibits the yeast vacuolar H+-ATPase.
J. Biol. Chem.
268:23325-23333[Abstract/Free Full Text].
|
| 31.
|
Klapholz, S., and R. E. Esposito.
1982.
A new mapping method employing a meiotic Rec mutant of yeast.
Genetics
100:387-412[Abstract/Free Full Text].
|
| 32.
|
Komano, H., and R. S. Fuller.
1995.
Shared functions in vivo of a glycosyl-phosphatidyl inositol-linked aspartyl protease, Mkc7, and the proprotein processing protease Kex2 in yeast.
Proc. Natl. Acad. Sci. USA
92:10752-10756[Abstract/Free Full Text].
|
| 33.
|
Lawrence, C. W.
1990.
Classical mutagenesis techniques.
Methods Enzymol.
194:273-281 |